MedTrace Logo

A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

NCT05556616 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2026-01-29

Study results available
· View outcomes & findings →

Summary

The main aims of this study are to test for any side effects from modakafusp alfa in combination therapy and to determine the recommended dose of combination therapy with modakafusp alfa. The dose of modakafusp alfa will be increased a little at a time until the highest dose that does not cause harmful side effects is found. Participants will be given modakafusp alfa through a vein.

Conditions

Interventions

DRUG

Carfilzomib

Carfilzomib intravenous infusion.

DRUG

Daratumumab

Daratumumab injection subcutaneously.

DRUG

Pomalidomide

Pomalidomide capsules orally.

DRUG

Modakafusp alfa

Modakafusp alfa intravenous infusion.

DRUG

Lenalidomide

Lenalidomide capsules orally.

DRUG

Bortezomib

Bortezomib injection subcutaneously.

Sponsors & Collaborators

  • Teva Branded Pharmaceutical Products R&D LLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-12
Primary Completion
2024-06-04
Completion
2024-06-04
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Israel
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05556616 on ClinicalTrials.gov